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1. Disease characteristics 
1.1 Name of the Disease (Synonyms): 
Congenital Primary Aphakia; CPAK (Anterior Segment Dysgenesis 2; ASGD2) 
 
1.2 OMIM# of the Disease:  
610256 
 
1.3 Name of the Analysed Genes or DNA/Chromosome Segments: 
FOXE3 
 
1.4 OMIM# of the Gene(s): 
601094 
 
1.5 Mutational Spectrum: 
Congenital primary aphakia (CPAK) is characterised by absence of the lens arising from 
failure of lens induction from the surface ectoderm and aborted lens development (1). It is 
caused by mutations in the FOXE3 gene, located on chromosome 1p33 and consists of a 
single exon 1981 bp long (NCBI reference sequence NM_012186.2). FOXE3 encodes the 
319 amino acid FOXE3 protein, a forkhead-related transcription factor involved in lens 
formation. Most cases are autosomal recessive and c.720C>A (p.Cys240Ter) is the most 
common variant associated with CPAK (2–5). There has been one report of a dominant 
pedigree with an affected family member with a right primary aphakia, sclerocornea, optic 
disc coloboma and microphthalmia, and left Peters anomaly with congenital cataract and 
mild microphthalmia resulting from a non-stop mutation c.958T>C (p.Ter320ArgextTer72) (6). 
 
It is important to note that both dominant and recessive mutations in FOXE3 are associated 
with a variable mixed phenotype of developmental eye disorders including anterior segment 
dysgenesis, microphthalmia, Peters anomaly, sclerocornea, early-onset cataract, glaucoma 
and ocular coloboma (4–7).  
 
1.6 Analytical Methods: 
Bi-directional fluorescent Sanger sequencing of coding and intron–exon boundaries of 
FOXE3 is the mainstay analytical method as an initial analysis. However, FOXE3 screening 
is being included on next-generation sequencing (NGS) exome gene panels in some 
laboratories. 
1.7 Analytical Validation 
Parallel bi-directional fluorescent Sanger sequencing of known controls is required to validate 
procedures. Diagnostic testing must be carried out within a laboratory environment working 
to standards compliant with the ISO 15189.  
 
1.8 Estimated Frequency of the Disease 
(Incidence at birth ("birth prevalence") or population prevalence. If known to be variable 
between ethnic groups, please report): 
CPAK is rare and the prevalence is unknown. Of the 9 families reported, 8 are 
consanguineous and 7 are of Pakistani origin, suggesting a higher incidence in this ethnic 
group (https://databases.lovd.nl/shared/diseases/02923).  
 1.9 Diagnostic Setting: 
 Yes. No. 
A. (Differential) diagnostics    
B. Predictive Testing    
C. Risk assessment in Relatives    
D. Prenatal    
 
Comment: Not applicable 
 
2. Test characteristics 
 
 
2.1 Analytical Sensitivity 
(proportion of positive tests if the genotype is present) 
 
The analytical sensitivity of bi-directional Sanger sequencing is estimated to be >98% for the 
detection of nucleotide base changes, small deletions and insertions in the regions analysed.  
 
 
2.2 Analytical Specificity 
(proportion of negative tests if the genotype is not present) 
 
The analytical specificity of bi-directional Sanger sequencing is >98% given current testing 
methodologies, based on false positives that may arise due to misinterpretation of rare 
polymorphic variants that rarely occur in Sanger sequencing.  
 
 
2.3 Clinical Sensitivity 
(proportion of positive tests if the disease is present) 
The clinical sensitivity can be dependent on variable factors such as age or family history. In 
such cases a general statement should be given, even if a quantification can only be made 
case by case. 
CPAK is a congenital eye defect presenting at birth with no lens formation and variably 
associated anterior segment dysgenesis. The clinical sensitivity is >98%. 
 
 
2.4 Clinical Specificity 
(proportion of negative tests if the disease is not present) 
The clinical specificity can be dependent on variable factors such as age or family history. In 
such cases a general statement should be given, even if a quantification can only be made 
case by case. 
 
A positive test in a patient without signs of this condition is extremely unlikely, and hence the 
clinical specificity will be high, nearing 100%. 
 
2.5 Positive clinical predictive value 
(life time risk to develop the disease if the test is positive) 
Estimated >99% for FOXE3 variants, as CPAK presents in infancy. 
 
2.6 Negative clinical predictive value 
(Probability not to develop the disease if the test is negative). 
Assume an increased risk based on family history for a non-affected person. Allelic and locus 
heterogeneity may need to be considered.  
Index case in that family had been tested: 
Nearly 100% if no CPAK. 
 
Index case in that family had not been tested: 
Nearly 100% if no CPAK. 
 
3. Clinical Utility 
3.1 (Differential) diagnostics: The tested person is clinically affected 
       (To be answered if in 1.9 "A" was marked) 
3.1.1 Can a diagnosis be made other than through a genetic test? 
 
No.  (continue with 3.1.4) 
Yes,  
 clinically.   
 imaging   
 endoscopy.   
 biochemistry.   
 electrophysiology.  
other (please describe): 
 
3.1.2 Describe the burden of alternative diagnostic methods to the patient 
If CPAK is suspected, a clinical diagnosis can be made based on clinical examination and 
confirmed with ultrasound. Anterior segment ultrasound biomicroscopy may aid detection of 
co-existent anterior segment dysgenesis.  
 
Due to the association of CPAK and the rubella virus, a TORCH complex evaluation is also 
recommended (8).  
 
3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?  
Clinical examination provides a cost effective diagnosis. 
 
3.1.4 Will disease management be influenced by the result of a genetic test? 
No.  
 
Yes.  
 Therapy (please describe)    
 Prognosis (please describe)  CPAK is often associated with other ocular anomalies, 
including microphthalmia, anterior segment dysgenesis, 
and glaucoma. Early diagnosis will enable prompt 
supportive treatment.  
 Management (please describe) CPAK should be managed by specialists with 
expertise in the condition. Supportive measures for 
those with sight impairment include involvement of 
social services. Regular follow-up will be required to 
monitor progression of associated anterior segment 
dysgenesis and glaucoma with medical and surgical 
interventions where needed. Intraocular surgery is not 
advised unless steps are taken to avoid inflammatory 
membrane formation and subsequent retinal 
detachment. Refractive refraction to reduce/prevent 
amblyopia. Genetic counselling will be offered to the 
family.  
 
3.2 Predictive Setting: The tested person is clinically unaffected but carries an 
increased risk based on family history 
     (To be answered if in 1.9 "B" was marked) 
3.2.1 Will the result of a genetic test influence lifestyle and prevention? 
 
If the test result is positive (please describe) CPAK is a congenital eye abnormality, 
therefore if it is not present at birth, it will not develop later in life. Identification of an 
unaffected carrier will inform family planning.  
 
If the test result is negative (please describe). The result will inform family planning. 
 
3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no 
genetic test has been done (please describe)? 
Vision can vary depending on severity of associated ocular anomalies. It can affect schooling 
and limit professions which require perfect vision. Hence, a clinically confirmed diagnosis can 
help in providing guidance regarding career choice.  
 
 
3.3 Genetic risk assessment in family members of a diseased person 
     (To be answered if in 1.9 "C" was marked) 
3.3.1 Does the result of a genetic test resolve the genetic situation in that family? 
Yes.  
 
3.3.2 Can a genetic test in the index patient save genetic or other tests in family 
members? 
If molecular testing has identified a FOXE3 mutation in the index patient, clinical examination 
can identify and exclude disease in relatives. However, further genetic tests are required to 
determine the carrier status. It is important to consider that heterozygous variants in FOXE3 
can cause associated ocular anomalies, so patients should be examined to exclude any 
manifestations. (4–7).  
 
 
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in 
a family member? 
Yes 
 
3.4 Prenatal diagnosis 
     (To be answered if in 1.9 "D" was marked) 
3.4.1 Does a positive genetic test result in the index patient enable a prenatal 
diagnosis? 
Yes, however, it has to be balanced with the severity of the condition. Primary aphakia is 
usually accompanied by anterior segment dysgenesis, which may prove extremely difficult to 
manage. Acting upon a positive result in terms of termination is not always advised as some 
level of treatment can be provided. Transabdominal ultrasound at 23 weeks gestation has 
detected CPAK (8). Identification of a causative FOXE3 mutation allows for pre-implantation 
diagnosis. 
 
 
4. If applicable, further consequences of testing 
Please assume that the result of a genetic test has no immediate medical consequences. Is 
there any evidence that a genetic test is nevertheless useful for the patient or his/her 
relatives? (Please describe) 
Genetic testing for FOXE3 variants will provide a molecular diagnosis. This yields information 
regarding carrier status and provide choices that would not otherwise be available to facilitate 
decision making for the patient and their family. Genetic testing is essential for defining 
inheritance patterns, carrier status and enabling effective genetic counselling with 
consequent implications for prenatal or pre-implantation genetic diagnosis.  
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Review of the analytical and clinical validity as well as of the clinical utility of DNA-based 
testing for mutations in the FOXE3 gene(s) in  diagnostic,  
        predictive and  
        prenatal settings and for  
        risk assessment in relatives. 
